Scientists test new drug cocktail in fight against tough blood cancer
NCT ID NCT01861314
Summary
This early-stage study is testing a combination of three drugs—bortezomib, sorafenib, and decitabine—to treat acute myeloid leukemia (AML). The main goal is to find the safest and most effective dose. The study is for adults with AML who are older, have a type that is hard to treat, or whose cancer has come back after previous treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.